WET AMD
Clinical trials for WET AMD explained in plain language.
Never miss a new study
Get alerted when new WET AMD trials appear
Sign up with your email to follow new studies for WET AMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One-Shot gene therapy aims to free patients from frequent eye injections
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help the eye make its own medicine, reducing or eliminating the need for li…
Matched conditions: WET AMD
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
One shot to fight blindness? gene therapy trial aims to replace frequent eye injections
Disease control Recruiting nowThis study is testing whether a single gene therapy injection can control wet age-related macular degeneration (a leading cause of blindness) as well as or better than the current standard of care, which requires eye injections every 1-4 months. About 284 participants, both new a…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One shot could replace years of eye injections for leading cause of blindness
Disease control Recruiting nowThis study is testing a single gene therapy injection for wet age-related macular degeneration (AMD), a major cause of vision loss. It aims to see if this one-time treatment can work as well as or better than the current standard of frequent eye injections. The trial will enroll …
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
One-Shot gene therapy aims to free patients from monthly eye injections
Disease control Recruiting nowThis large, late-stage trial is testing whether a single gene therapy injection into the eye (called LX102) can work as well as or better than the standard monthly eye injections for wet age-related macular degeneration. The main goal is to see if the one-time treatment can impro…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC